DPP-4 Therapy Center

Bristol-Myers Squib and AstraZeneca’s experimental diabetes drug Onglyza significantly improves blood sugar control when added to older medicines, researchers said at EASD.

Alogliptin, an investigational once-daily oral drug for type 2 diabetes, showed good efficacy and safety both as monotherapy and together with standard agents, researchers in five phase III trials stated at ADA Scientific Sessions.

Results from a 24-week Phase III study showed that saxagliptin, a selective, reversible inhibitor of the dipeptidyl peptidase (DPP-4) enzyme in development by Bristol-Myers Squibb Company and AstraZeneca produced significant reductions in key measures of glucose control, A1C, FPG and PPG in treatment naïve people with type 2 diabetes compared …

Novartis expected to be in the market this year with Galvus, But the FDA is requiring more studies to determine Galvus’s safety, so they will not resubmit until probably mid-2009

The first ever human data for Alogliptin, Takeda’s investigational compound for Type 2 diabetes, Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.

Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) approved JANUMET™, the first and only tablet combining a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin (also known as JANUVIA™), and metformin for the treatment of type 2 diabetes.

According to a new report from Decision Resources, the New Novel Drug Classes Will Account for 76% of the Type 2 Diabetes Market by 2020, even though they are not even available in the US at this time.

A once-daily oral agent that preserves the action of the glucagon like peptide GLP-1, improves glycemic control in patients who are inadequately controlled with metformin.